Italian consensus guidelines for chronic pancreatitis by Frulloni, L. et al.
Digestive and Liver Disease 42S (2010) S381–S406
Contents lists available at ScienceDirect
Digestive and Liver Disease
journa l homepage: www.e lsev ier .com/ locate /d ld
Italian consensus guidelines for chronic pancreatitis
Luca Frulloni1, °, Massimo Falconi2, Armando Gabbrielli1, Ezio Gaia3, Rossella Graziani4,
Raffaele Pezzilli5, Generoso Uomo6, Angelo Andriulli7, Gianpaolo Balzano8, Luigi Benini1,
Lucia Calculli9, Donata Campra10, Gabriele Capurso11, Giulia Martina Cavestro12,
Claudio De Angelis13, Luigi Ghezzo14, Riccardo Manfredi4, Alberto Malesci15, Alberto Mariani16,
Massimiliano Mutignani17, Maurizio Ventrucci18, Giuseppe Zamboni4, Antonio Amodio1, Italo Vantini1
1Department of Medicine, University of Verona, Verona, Italy
2 Department of Surgery, University of Verona, Verona, Italy
3 Gastroenterology and Digestive Endoscopy, A.O.U. San Luigi, Turin, Italy
4 Department of Pathology and Radiology, University of Verona, Verona, Italy
5 Pancreas Unit, Department of Digestive Diseases and Internal Medicine, University of Bologna. Bologna, Italy
6 Department of Internal Medicine, Cardarelli Hospital, Naples, Italy
7 Division of Gastroenterology and Digestive Endoscopy, IRCCS “Casa Sollievo Sofferenza” Hospital, San Giovanni Rotondo, Italy
8 Department of Surgery, Pancreas Unit, San Raffaele Scientiﬁc Institute, Milan, Italy
9 Department of Radiology, Sant’Orsola-Malpighi Hospital, Bologna, Italy
10 U.O.A. Chirurgia Generale 7, Azienda Ospedaliera S. Giovanni Battista di Torino, Turin, Italy
11 Digestive and Liver Disease Unit, S. Andrea Hospital, University La Sapienza, Rome, Italy
12 Department of Clinical Science, University of Parma, Parma, Italy
13 Department of Gastro-Hepatology, Molinette Hospital, Turin, Italy
14 Digestive Endoscopy Unit, S. Croce e Carle Hospital, Cuneo, Italy
15 Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Milan, Italy
16 Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy
17 Digestive Endoscopy Unit, Catholic University, Rome, Italy
18 Department of Internal Medicine and Gastroenterology, Bentivoglio Hospital, Bologna, Italy
Promoter: Italian Association for the Study of the Pancreas (AISP)
AISP representatives: Claudio Bassi (President) and Gianfranco Delle Fave (past President)
Project Coordinator: Luca Frulloni
Methodology and Process Coordinator: Italo Vantini
Scientiﬁc Board: Massimo Falconi, Luca Frulloni, Armando Gabbrielli, Rossella Graziani, Raffaele Pezzilli, Italo Vantini
Working party participants: Angelo Andriulli, Gianpaolo Balzano, Luigi Benini, Lucia Calculli, Donata Campra, Gabriele
Capurso, Giulia Martina Cavestro, Claudio De Angelis, Massimo Falconi, Ezio Gaia, Luigi Ghezzo, Armando Gabbrielli, Rossella
Graziani, Riccardo Manfredi, Alberto Malesci, Alberto Mariani, Massimiliano Mutignani, Raffaele Pezzilli, Generoso Uomo,
Maurizio Ventrucci, Giuseppe Zamboni
Consensus non-voting chairman: Italo Vantini
Representative of the non-governmental organization for citizen and patient rights Cittadinanzattiva: Flavio Magarini
Consensus participants: Luca Albarello (Milano), Sergio Alﬁeri (Roma), Antonio Amodio (Verona), Angelo Andriulli (San
Giovanni Rotondo), Marcello Anti (Viterbo), Piergiorgio Arcidiacono (Milano), Luca Baiocchi (Brescia), Gianpaolo Balzano
(Milano), Luigi Benini (Verona), Debora Berretti (Udine), Pietro Boraschi (Pisa), Elisabetta Buscarini (Crema), Lucia Calculli
(Bologna), Antonio Carroccio (Palermo), Donata Campra (Torino), Mario Roberto Celebrano (Verona), Gabriele Capurso (Roma),
Riccardo Casadei (Bologna), Giulia Martina Cavestro (Parma), Fausto Chilovi (Bolzano), Rita Conigliaro (Modena), Luigi
Dall’Oglio (Roma), Claudio De Angelis (Torino), Michele De Boni (Feltre), Giovanni De Pretis (Trento), Sebastiano Di Priolo
(Cagli), Pier Luigi Di Sebastiano (San Giovanni Rotondo), Giovanni Battista Doglietto (Roma), Massimo Falconi (Verona),
Marco Filauro (Genova), Giuseppe Frieri (L’Aquila), Luca Frulloni (Verona), Arnaldo Fuini (Verona), Ezio Gaia (Torino),
Luigi Ghezzo (Cuneo), Armando Gabbrielli (Verona), Rossella Graziani (Verona), Pietro Loriga (Cagliari), Giampiero Macarri
° Corresponding author. Luca Frulloni. Cattedra di Gastroenterologia, Policlinico GB Rossi, P.le LA Scuro, 10, 37134 Verona, Italy.
Tel.: +39 045 8074191; Fax: +39 045 8205584. E-mail address: luca.frulloni@univr.it (L. Frulloni).
1590-8658/$30© 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
S382 L. Frulloni et al. / Digestive and Liver Disease 42 Suppl. 6 (2010) S381–S406
(Fermo), Gianpiero Manes (Milano), Riccardo Manfredi (Verona), Alberto Malesci (Milano), Alberto Mariani (Milano), Paolo
Massucco (Torino), Stefano Milani (Firenze), Massimiliano Mutignani (Roma), Claudio Pasquali (Padova), Paolo Pederzoli
(Verona), Raffaele Pezzilli (Bologna), Michele Pietrangeli (Cagliari), Rodolfo Rocca (Torino), Domenico Russello (Catania),
Walter Siquini (Ancona), Mario Traina (Palermo), Generoso Uomo (Napoli), Luigi Veneroni (Rimini), Maurizio Ventrucci
(Bentivoglio), Maurizio Zilli (Udine), Giuseppe Zamboni (Verona).
Abstract
This paper gives practical guidelines for diagnosis and treatment of chronic pancreatitis. Statements have been elaborated by working teams
of experts, by searching for and analysing the literature, and submitted to a consensus process by using a Delphi modiﬁed procedure. The
statements report recommendations on clinical and nutritional approach, assessment of pancreatic function, treatment of exocrine pancreatic
failure and of secondary diabetes, treatment of pain and prevention of painful relapses. Moreover, the role of endoscopy in approaching
pancreatic pain, pancreatic stones, duct narrowing and dilation, and complications was considered. Recommendations for most appropriate use
of various imaging techniques and of ultrasound endoscopy are reported. Finally, a group of recommendations are addressed to the surgical
treatment, with deﬁnition of right indications, timing, most appropriate procedures and techniques in different clinical conditions and targets,
and clinical and functional outcomes following surgery.
© 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Keywords: Pancreatitis, chronic; Complications; Surgery; Radiography; Therapy; Ultrasonography; Cholangiopancreatography, endoscopic retrograde;
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1. Introduction
Chronic pancreatitis is characterized by an inﬂammatory
process of the pancreas, progressively destroying the gland,
that leads to pancreatic exocrine and endocrine dysfunction.
Several risk factors have been identiﬁed and/or candidated, but
in a not negligible proportion of patients the disease remains
idiopathic. Clinically, the early phase is characterized by
pain or recurrent episodes of pancreatitis and complications,
whereas in the advanced phase symptoms are related to the
onset of exocrine and/or endocrine insufﬁciency. Chronic
pancreatitis in the advanced phase is considered a risk factor
for pancreatic cancer [1–3]. The therapeutic approach to
chronic pancreatitis may be medical, surgical or endoscopic.
A number of recommendations for the diagnosis and
treatment of chronic pancreatitis have been published in
different countries [1–6], but no systematic guidelines have
been published up to now.
The aim of this study was to develop guidelines for the
clinical and therapeutic management of chronic pancreatitis,
by using a rigorous methodology that could be used clinically
by gastroenterologists, internists, radiologists, surgeons, and
primary care physicians.
On the basis of imaging and molecular biology, par-
ticular forms of chronic pancreatitis have been described,
e.g. autoimmune pancreatitis [7–10], paraduodenal pancre-
atitis [11,12], and pancreatitis associated with gene muta-
tions [11,13–15]. However, nowadays there is no international
agreement about their deﬁnition and/or management. There-
fore, statements speciﬁcally addressed to these particular
forms of the disease were not considered.
2. Methods
The primary aim of this document was to provide clinical
guidelines for appropriate management of chronic pancreati-
tis. Particular forms of chronic pancreatitis (autoimmune pan-
creatitis, paraduodenal pancreatitis and pancreatitis associated
with gene mutations) were preliminarily excluded because
available data were considered insufﬁcient for generating
speciﬁc guidelines so far.
Promoter of these guidelines was the Italian Association for
the Study of the Pancreas (Associazione Italiana per lo Studio
del Pancreas, AISP).
The guidelines were endorsed by the Italian Society
of Gastroenterology (Societa` Italiana di Gastroenterologia,
SIGE), the Italian Association for Gastroenterologists
and Endoscopists (Associazione Italiana Gastroenterologi ed
Endoscopisti Ospedalieri, AIGO), the Italian Society for
Gastrointestinal Endoscopy (Societa` Italiana di Endoscopia
Digestiva, SIED), the Italian Society of Surgery (Societa`
Italiana di Chirurgia, SIC), and the Italian Society of Medical
Radiology (Societa` Italiana di Radiologia Medica, SIRM).
AISP identiﬁed a Scientiﬁc Board of Experts. The Scientiﬁc
Board deﬁned methodology and targets, and acted as devel-
oper and reviewer.
The methodology to process guidelines involved ﬁve
steps:
(1) The scientiﬁc board selected ﬁve main areas of interest
in chronic pancreatitis: clinics, functional aspects and
medical therapy, imaging, endoscopy, and surgery.
(2) For each topic, a working party was created, with a group
of at least four experts each and a chairman, who selected,
together with the scientiﬁc board and its chairman,
clinically relevant, clear, answerable questions, focused on
current practice and areas of controversy. These questions
were circulated around the working parties to share
relevance, improve clarity, and avoid duplication. Experts
were chosen on the basis of demonstration of knowledge
and competence on chronic pancreatitis and on speciﬁc
topics by professional expertise and publication/research.
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Table 1a
Levels of evidence based on the Oxford Centre for Evidence-Based Medicine
Level Individual study Technique
1a Systematic review (SR) with homogeneity of level 1 diagnostic studies SR with homogeneity of randomized controlled trials (RCTs)
1b Validation cohort study with good reference standards Individual RCT, with narrow conﬁdence interval
1c Speciﬁcity is so high that a positive result rules in the diagnosis (“SpPin”) or
sensitivity is so high that a negative result rules out the diagnosis
All or none
2a SR with homogeneity of level >2 diagnostic studies SR with homogeneity of cohort studies
2b Exploratory cohort study with good reference standards Individual cohort study (including low-quality RCT, for example
<80% follow-up). “Outcomes” research; ecological studies
3a SR with homogeneity of 3b and better studies SR with homogeneity of case–control studies
3b Non-consecutive study; or without consistently applied reference standards Individual case–control study
4 Case–control study, poor or non-independent reference standard Case series (and poor quality cohort and case–control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology,
bench research, or “ﬁrst principles”
Expert opinion without explicit critical appraisal, or based on
physiology, bench research, or “ﬁrst principles”
Table 1b
Grades of recommendation based on the Oxford Centre for Evidence-Based Medicine
Grade Evidence base
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolation from level 1 studies
C Level 4 studies or extrapolation from level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
A preliminary meeting of working parties was held in
Rome (April 2008) in order to share methods, aims,
timelines, and the entire guideline processing.
(3) The working parties independently carried-out a system-
atic search for and analysis of the literature on their
topics before March 2009, by using Medline/PubMed
and the Cochrane data base for identifying the evidence
to support the statements. Each recommendation was
graded according to the Oxford Centre for Evidence-
Based Medicine, based on the level of evidence (EL)
(Tables 1a,b).
(4) The working parties developed initial statements within
six months and attributed them a grade (strength) of
recommendation (RG) (from A to D, consistent with the
level of evidence) (Table 1). They were recommended to
develop clear, unequivocal, sufﬁciently short statements
that can be applied in clinical practice. A draft of
provisional statements was written by the chairman of
each group, and circulated within the group. A redrafted
document was then prepared. Moreover, a comment for
each statement was elaborated by the group and chairman,
but that was not submitted to vote/formal agreement.
(5) The working parties met twice, on January 22nd–
23rd 2009 and on June 11th–12th 2009, for achieving a
ﬁrst agreement on statements by using a simpliﬁed scale
(agreement/disagreement); they voted using a modiﬁed
Delphi procedure until a minimum agreement level as
high as 67% was achieved for each statement. Statements
were then submitted to the scientiﬁc board and chairman,
who wrote an advanced version, and feedback to working
parties was given for each iteration.
On November 16th−17th 2009 a consensus meeting was
held in Verona. The consensus group consisted of 52
participants, selected by taking into account diversity in
competence and expertise in various aspects of chronic
pancreatitis, and geographical distribution. The consensus
group was led by a non-voting chairman (I.V.), and included
experts of working parties and multi-disciplinary profession-
als/experts such as gastroenterologists, surgeons, radiologists,
pathologists, and general practitioners. A representative of the
non-governmental organization for citizen and patient rights
Cittadinanzattiva took part as a non-voting observer of the
meeting. Statements were submitted to the global consensus
group for a ﬁrst anonymous keypad voting (Delphi process)
without any explanation or justiﬁcation. The Delphi process
allowed a change of view from a previously held position,
and avoided any embarrassment of participants or inﬂuence
on the individual vote. The agreement/disagreement level was
scored on a six-point Likert scale as follows: A+: agree
strongly; A: agree with minor reservation; A−: agree with
major reservation; D−: disagree with major reservation;
D: disagree with minor reservation; D+: disagree strongly.
Level of agreement was expressed as percentage of each
point of the scale. Immediate feedback was given to
participants on a screen. They were prompted by the non-
voting chairman to discuss statements, and to suggest changes
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in the presence of controversy (<67% agreement) or of a
sum A+ and A <80%. Statements were then reviewed by
a jury (the scientiﬁc board, with the exclusion of the non-
voting chairman). Two statements addressing topics already
contained in other statements were included in the latter.
After an open discussion driven by the non-voting chairman
and focused on controversial recommendations, statements
were submitted to a second anonymous keypad vote. In the
review process, four statements needed further, though small
changes because of insufﬁcient clarity of wording and then
were again submitted to the global consensus group for a
further vote, before the ﬁnal version was written. The entire
consensus group work and discussion was recorded on tape.
Out of 55 statements presented, 53 remained and these were
approved.
The format of recommendations comprised the question,
the statement, its level of evidence and strength of recom-
mendation, and the percent agreement of the global consensus
group with the ﬁnal version. In the present document the
statements are accompanied by qualifying comments, written
by each working party and reviewed by the scientiﬁc board, by
taking into account relevant comments and suggestions of the
global consensus group too. Statements and their comments
should be read together and not alone. In some areas the
evidence level is low, reﬂecting the paucity of randomized
trials and of good quality diagnostic studies. For some topics
the expert opinion was considered, where appropriate.
3. Statements
3.1. Clinics, functional aspects and medical therapy (C)
3.1.1. Clinics
Working party: Generoso Uomo (Coordinator), Angelo
Andriulli, Gabriele Capurso, Giulia Martina Cavestro,
Raffaelle Pezzilli.
3.1.2. Functional aspects and medical therapy
Working party: Ezio Gaia (Coordinator), Luigi Benini,
Alberto Malesci, Maurizio Ventrucci.
This section concerns clinical aspects, pancreatic function
and medical therapy of the disease. Long-term outcome, pain,
pancreatic failure, diabetes and risk of cancer were consid-
ered. The section includes clinical features, risk factors − such
as alcohol and smoking − and the effect of their withdrawal
on the clinical course of the disease, treatment of exocrine
pancreatic failure, treatment of pain and prevention of painful
relapses, and therapy of secondary diabetes. The role of
pancreatic enzymes and of antioxidants in preventing pain
is also discussed. The assessment of pancreatic dysfunction
with clinical parameters and functional tests is considered for
the identiﬁcation of patients with exocrine insufﬁciency and
for appropriate indication to enzyme-containing preparation
therapy. Type, dose, timing and criteria of efﬁcacy of pan-
creatic enzyme therapy are considered as well as nutritional
approach.
C.1: Are there different patterns of pain in chronic
pancreatitis?
Statement (EL 2b − RGB): Episodic or persistent types
of pain can be present in the clinical picture of chronic
pancreatitis.
Consensus Levels of Agreement:
A+ 81%; A 14.1%; A− 4.8%; D− 0%; D 0%; D+ 0%
Abdominal pain is the dominant symptom of chronic
pancreatitis. Throughout the course of the disease, 80−90%
of patients complain of pain, whereas the remaining 10−20%
of individuals have “painless pancreatitis” [2,12,16–18]. Pain
is usually recurrent and it may be either episodic (type A:
short-lived bouts of pain, lasting less than 10 days with
long pain-free intervals; more frequent in idiopathic senile
or late-onset chronic pancreatitis) or persistent (type B:
more severe and long-lasting episodes separated by 1−2-
month pain-free intervals, more frequent in alcoholic chronic
pancreatitis and idiopathic juvenile or early-onset chronic pan-
creatitis) [2,12,16–19]. Whether pain spontaneously burns out
in late stages of uncomplicated chronic pancreatitis is still a
matter of debate [5,20–26].
C.2: How can the intensity of pain be measured in chronic
pancreatitis?
Statement (EL 4 − RGD): There are no speciﬁcally
validated tools to score pain in chronic pancreatitis.
Consensus Levels of Agreement:
A+ 80.9%; A 14.9%; A− 2.1%; D− 2.1%; D 0%; D+ 0%
Numerical scales ranging from “no pain” to “most severe
pain”, and the visual analog scale (VAS) are largely utilized
in clinical trials [20]. A pain score speciﬁcally designed
for chronic pancreatitis was published in 1995 [27]. This
score is based on four domains that concern frequency of
pain, its intensity (as indicated by VAS), need for analgesics,
and disease-related inability to work; the score ranges from
0 to 100, with higher scores indicating more severe pain.
This score was successfully employed in a recent prospective
controlled trial on the treatment of chronic pancreatitis [28].
C.3: Which analgesics are recommended for treating pain in
chronic pancreatitis?
Statement (EL 4 − RGC): Non-steroidal anti-inﬂammatory
drugs (NSAIDs) and narcotics are recommended for treating
pain in chronic pancreatitis.
Consensus Levels of Agreement:
A+ 84.8%; A 8.7%; A− 2.2%; D− 2.2%; D 2.2%; D+ 0%
Conventional NSAIDs represent the ﬁrst approach to
manage pain in chronic pancreatitis, but most patients with
relentless pain require narcotics [5,20,21,27,29,30]. Tramadol
should be initially preferred to morphine because of less
interference with gastrointestinal functions [29]. Opioids in
different formulations are similarly effective [20].
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C.4: Does smoking withdrawal reduce pain relapses in
chronic pancreatitis?
Statement (EL 4 − RGC): Smoking withdrawal is
moderately effective in reducing pain relapses in chronic
pancreatitis.
Consensus Levels of Agreement:
A+ 48.9%; A 26.7%; A− 13.3%; D− 2.2%; D 4.4%; D+ 4.4%
It is difﬁcult to distinguish the role of smoking from that
of alcohol consumption in causation and clinical evolution
of chronic pancreatitis, as cigarette smoking is often an
inseparable habit in alcoholics [21–26,28,30,31]. Moreover,
alcohol withdrawal is quite often not associated with smoking
withdrawal. Retrospective data indicated a beneﬁcial effect of
smoking withdrawal to reduce/avoid pain and complications
in chronic pancreatitis [32,33]. Experts recommend smoking
withdrawal for patients with chronic pancreatitis [18].
C.5: Is alcohol withdrawal recommended for reducing pain
in chronic pancreatitis?
Statement (EL 2b − RGB): Alcohol withdrawal is
recommended for reducing pain in chronic pancreatitis.
Consensus Levels of Agreement:
A+ 90.2%; A 9.8%; A− 0%; D− 0%; D 0%; D+ 0%
Abstinence from alcohol is an important factor inﬂuencing
pain in patients with alcoholic pancreatitis. Abstainers have
a slower rate of deterioration of pancreatic function and
a better response to pain control by therapy than non-
abstainers [18,34–40].
Moreover, exocrine pancreatic insufﬁciency does not progress
after alcohol withdrawal [37].
C.6: Is chronic pancreatitis a risk factor for pancreatic
cancer?
Statement (EL 1b − RGB): Incidence of pancreatic cancer
is increased in long-lasting chronic pancreatitis.
Consensus Levels of Agreement:
A+ 41.3%; A 26.1%; A− 15.2%; D− 4.3%; D 0%; D+ 0%
The relation of chronic pancreatitis to pancreatic cancer
has been addressed in several epidemiologic case–control
and cohort studies. Most studies of pancreatic cancer with
a case–control design [41–50] did not report the type of
pancreatitis (acute or chronic). Thus, we examined the only
one study in which the chronic type of pancreatitis was
clearly stated [51] and having a high number of patients. In
this paper a clear relationship between chronic pancreatitis
and pancreatic cancer was found (OR 2.23; 95%CI 1.43–
3.49). Cohort studies [52–60] conﬁrmed the relationship
between chronic pancreatitis and pancreatic cancer. It should
be underlined that the ﬁndings of the cohort studies must be
viewed in the light of potential methodological problems: ﬁrst,
the recruitment of patients began from 1946 to 1973 in most
studies [53–56,59,60], when it was difﬁcult to distinguish
chronic pancreatitis from pancreatic cancer; second, cancer
was not conﬁrmed histologically in all patients evaluated;
third, a number of patients may have had a slower-growing
cancer, such as a cystadenocarcinoma or intraductal papillary
neoplasia. Finally, the possible presence of a misclassiﬁcation
bias is well reported in the study of Lowenfels [56]. In
this study the risk of pancreatic cancer was markedly lower
when data for the ﬁrst two years of observation were
excluded. In fact, the standardized incidence ratio was 26.3
(95%CI 19.9–34.2) for all patients, 16.5 (95%CI 11.1–
23.7) for patients with two or more years of follow-up,
and 14.4 (95%CI 8.5–22.8) for patients with ﬁve or more
years of follow-up. These data have been conﬁrmed in
other reports [51,53,55,60]. We need further studies to re-
evaluate the real risk rate of pancreatic adenocarcinoma in
patients with chronic pancreatitis. The prerequisite is an
unequivocal diagnosis of chronic pancreatitis through more
modern diagnostic tools.
C.7: Can structured questionnaires be recommended
to evaluate the self-reported outcome in chronic
pancreatitis?
Statement (EL 1b − RGB): Structured questionnaires are
useful to evaluate the well-being of patients with chronic
pancreatitis.
Consensus Levels of Agreement:
A+ 50%; A 31.3%; A− 12.5%; D− 6.3%; D 0%; D+ 0%
Many structured questionnaires have been utilized to assess
the well-being of patients with chronic pancreatitis [20,27,61–
69]. SF-12, SF-36, EORTC QLQ C-30, and GIQLI have all
been proved useful. SF-12 is easier and more rapid than
other tools, and gives the same information as SF-36 and
EORTC QLQ C-30 [66]. However, it should be stressed that
all questionnaires refer only to the month before completion
of the questionnaire.
C.8: Is a change in the diet content of carbohydrates, fats
and proteins indicated in chronic pancreatitis?
Statement (EL 5 − RGD): A reduction in dietary fats is
recommended if steatorrhea is severe and not responding to
medical treatment.
Consensus Levels of Agreement:
A+ 73.2%; A 14.6%; A− 9.8%; D− 0%; D 0%; D+ 2.4%
There is no speciﬁc study addressing the type of macronu-
trient intake which may prevent late consequences of the
disease. Theoretically, complex carbohydrates and dietary
ﬁbres may be useful to delay the onset of diabetes. Dietary
ﬁbres are often restricted in patients with chronic pancreatitis
on the belief that they adsorb digestive enzymes and therefore
interfere with their action [70,71]. This concept is however
based on weak and indirect data (e.g., triolein breath tests
that may be inﬂuenced by the delayed gastric emptying by
ﬁbres) [72]. No formal data are available on the need to reduce
fat intake in patients with pancreatic steatorrhea, but severe
steatorrhea is distressing, socially embarrassing, and may
facilitate the occurrence of urinary oxalate stones. However,
a reduction in fat intake is not easily accomplished, and
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may worsen the nutritional balance and vitamin levels. No
interventional studies are available on the need to restrict
alimentary fat in patients with pancreatic insufﬁciency.
C.9: Are medium-chain triglycerides (MCT) indicated in the
diet of patients with chronic pancreatitis and pancreatic
exocrine insufﬁciency?
Statement (EL 1b − RGB): MCT are not indicated in
patients with chronic pancreatitis and pancreatic exocrine
insufﬁciency.
Consensus Levels of Agreement:
A+ 82.6%; A 15.2%; A− 2.2%; D− 0%; D 0%; D+ 0%
MCTs have not been shown to be effective in patients
suffering from chronic pancreatitis with exocrine pancreatic
insufﬁciency. Moreover, their poor palatability and high cost
reduce the compliance of patients. Evidence exists that also
MCTs require enzyme supplements for proper digestion and
absorption [73]. For instance, patients with severe pancreatic
insufﬁciency on tube feeding require pancreatic supplements
for the digestion not only of polymeric formulas (which
contain long-chain triglycerides), but also of elemental ones
(which contain medium-chain triglycerides) [74,75].
C.10: Is vitamin supplementation recommended in patients
with chronic pancreatitis?
Statement (EL 1c − RGB): Parenteral injection of
lipophylic vitamins is strongly recommended in patients
with severe exocrine pancreatic insufﬁciency.
Consensus Levels of Agreement:
A+ 72.9%; A 14.6%; A− 8.3%; D− 2.1%; D 0%; D+ 2.1%
Serum levels of lipophylic vitamins are reduced due
to malabsorption caused by severe pancreatic failure [76].
This reduction has been conﬁrmed repeatedly mainly for
vitamin D, even before the onset of overt steatorrhea [77–79].
The parenteral administration of these vitamins is therefore
indicated in patients with reduced serum levels or in the
presence of clinical features of malabsorption.
C.11: Are antioxidant supplements useful in chronic
pancreatitis?
Statement (EL 1b − RGC): Chronic use of oral
antioxidant supplements may be useful to prevent painful
recurrences of chronic pancreatitis.
Consensus Levels of Agreement:
A+ 30.1%; A 30.2%; A− 20.9%; D− 7%; D 9.3%; D+ 2.3%
Only a single controlled clinical trial demonstrated that oral
supplementation with antioxidants (selenium, beta-carotene,
ascorbic acid, tocopherol) can be useful for the prevention of
painful relapses [80]. The results of this study need to be con-
ﬁrmed. Previous studies were negative or inconclusive [63,81–
85]. Though 80% consensus rate was reached, one in ﬁve
participants agreed with major reservation only. Therefore, it
was considered that further studies should be carried out to
conﬁrm the above mentioned study, and the recommendation
grade was set lower than the level of evidence.
C.12: Is pancreatic enzyme supplementation indicated in
chronic pancreatitis?
Statement (EL 1a − RGA): Pancreatic enzyme
supplementation is indicated in patients with chronic
pancreatitis and exocrine pancreatic insufﬁciency.
Consensus Levels of Agreement:
A+ 76.6%; A 17%; A− 4.3%; D− 2.1%; D 0%; D+ 0%
The main clinical consequences of chronic pancreatitis
are malnutrition and steatorrhea, both due to fat maldiges-
tion [86]. Pancreatic enzyme supplementation improves fat
absorption in patients with chronic pancreatitis and pancreatic
exocrine insufﬁciency [87]. Enzyme supplementation therapy
is able to normalize nutritional parameters such as liposoluble
vitamins, prealbumin, and ferritin in patients without overt
steatorrhea [86,88]. Steatorrhea occurs late in chronic pan-
creatitis (after a median of 10 to 12 years since the onset
of the disease in about 50% of patients) [88], and it may
be much more common than expected on clinical grounds
only [89]. Therefore, enzyme supplementation may be con-
sidered in patients with long-lasting chronic pancreatitis [89].
Adequate treatment is relevant to avoid malnutrition-related
morbidity and mortality. For instance, osteoporosis is quite
common in chronic pancreatitis, due to malabsorption of
vitamin D [78,79].
C.13: Is quantitative measurement of faecal fat required
before prescription of pancreatic enzymes?
Statement (EL 2b − RGB): Quantitative measurement
of faecal fat is not mandatory for prescribing pancreatic
enzymes.
Consensus Levels of Agreement:
A+ 64%; A 24%; A− 4%; D− 2%; D 2%; D+ 0%
Clinical diagnosis of steatorrhea (loose, greasy, foul-
smelling large stools) is reached relatively late in the course
of chronic pancreatitis [77]. A 72-h fecal fat collection
to evaluate the coefﬁcient of fat absorption (CFA) is the
“gold standard” for diagnosis of steatorrhea; it is useful for
clinical trials [88], but is not available or feasible in many
instances. Pancreatic enzymes are clearly recommended to
treat patients with overt steatorrhea. In chronic pancreatitis
with a strong suspicion of maldigestion (weight loss, muscle
wasting, osteopenia) enzyme therapy may be introduced even
in absence of measurement of steatorrhea and in face of
macroscopically normal stool appearance [89].
C.14: Does pancreatic enzyme supplementation improve the
quality of life in patients with chronic pancreatitis?
Statement (EL 4 − RGD): Pancreatic enzyme
supplementation improves the quality of life in chronic
pancreatitis.
Consensus Levels of Agreement:
A+ 48.9%; A 29.8%; A− 10.6%; D− 2.1%; D 4.3%; D+ 4.3%
Adequately dosed pancreatic enzyme supplementation sig-
niﬁcantly improved QoL both in patients with newly diag-
nosed and never treated chronic pancreatitis, and in patients
receiving under-dosed pancreatic enzyme supplementation.
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In the ﬁrst group, working ability, cognitive functioning,
ﬁnancial strain, and overall QoL scores had improved
signiﬁcantly after one month of enzyme supplementation
therapy. Similarly, in the second group, with more severe
exocrine insufﬁciency, QoL improved with a better control
of maldigestion. Signiﬁcant correlations were found in both
groups between the increase in QoL and body weight or
improvement in fecal fat excretion [61].
C.15: Is pancreatic enzyme supplementation recommended
for reducing frequency and severity of painful relapses
in chronic pancreatitis?
Statement (EL 1a − RGA): Pancreatic enzyme
supplementation is not recommended for reducing frequency
and severity of painful relapses in chronic pancreatitis.
Consensus Levels of Agreement:
A+ 93.2%; A 4.1%; A− 2%; D− 0%; D 0%; D+ 0%
A meta-analysis showed that pancreatic enzyme supplemen-
tation did not reduce pain and relapses in patients with chronic
pancreatitis [90,91].
C.16: Should proton pump inhibitors (PPI) be added to
pancreatic enzyme supplementation in the treatment
of pancreatic exocrine insufﬁciency in chronic
pancreatitis?
Statement (EL 2a − RGC): Proton pump inhibitors should
be added if steatorrhea is not controlled by pancreatic
enzyme supplementation alone.
Consensus Levels of Agreement:
A+ 62.2%; A 22.2%; A− 11.1%; D− 0%; D 0%; D+ 4.4%
The concomitant use of PPI is not indicated in patients with
an adequate response to pancreatic enzyme supplementation
therapy. However, patients with pancreatic insufﬁciency can
have a severely impaired pancreatic bicarbonate secretion
which may be insufﬁcient to neutralize the acidity of the
chyme in the duodenum [86,92]. This can impair the enzyme
supplementation therapy, even when adequate or high enzyme
doses are given. Addition of PPI is recommended in refractory
steatorrhea only. There is however no clear evidence of a
clinical advantage for PPI addition by using enteric-coated-
microgranule enzyme preparations [93,94].
C.17: Which pancreatic enzyme formulation should be used
and how should it be administered?
Statement (EL 1b − RGA): Pancreatic enzyme
formulations with enteric-coated pH-sensitive
minimicrospheres and high lipase content should be used.
Statement (EL 2b − RGB): The recommended dose is
25,000−40,000 units of lipase per meal. Pancreatic enzymes
should be administered during or just after meals.
Consensus Levels of Agreement:
A+ 82.2%; A 17.8%; A− 0%; D− 0%; D 0%; D+ 0%
The efﬁcacy of pancreatic enzyme preparations depends on
the enzyme activity released in the duodenum together with
the chyme duodenal load. In pancreatic enzyme supplements,
pancrelipase is formulated within pH-sensitive enteric-coated
microspheres which mix with the meal in the stomach, protect
their enzyme content from gastric acidity, and empty in the
duodenum with the chime, where coating rapidly disintegrates
at pH 5.5 to release enzymes from the microspheres [86,95].
Minimicrospheres of 1.0 to 1.2mm in diameter have been
shown to be emptied simultaneously with the meal and are
associated with a 25% higher therapeutic efﬁcacy compared
to 1.8−2.0mm microspheres [86,96]. There is no evidence
that minimicrospheres with a lower diameter increased the
efﬁcacy of enzyme supplementation on steatorrhea. Dosage
should be tailored according to the severity of maldigestion
and fat content of the meal. A dosage of 25,000–40,000 IU of
lipase per meal is recommended [95]. A recent randomized,
placebo-controlled trial in patients with chronic pancreatitis
has shown that 40,000 IU of lipase per meal and 20,000 IU
per snack were able to increase fat absorption, to decrease
stool frequency and to improve stool consistency [97]. A
median dose of 40,000 IU of lipase per meal for one
year normalized fat absorption, signiﬁcantly increased body
weight, normalized retinol-binding protein and prealbumin in
most patients with chronic pancreatitis [88]. The efﬁcacy of
enzyme supplementation therapy seems to be higher when
enzymes are administered during or just after meals [98].
C.18: How can the efﬁcacy of pancreatic enzyme
supplementation be assessed?
Statement (EL 2a − RGB): The clinical improvement
of the nutritional parameters and the normalization of
gastrointestinal symptoms are sufﬁcient criteria to evaluate
the efﬁcacy of pancreatic enzymes. In non-responder
patients laboratory methods for assessing fat absorption
(Coefﬁcient of Fat Absorption, 14C breath test) may be
used.
Consensus Levels of Agreement:
A+ 68.1%; A 29.8%; A− 2.1%; D− 0%; D 0%; D+ 0%
Nutritional parameters and clinical features (body weight,
stool weight and aspect) can be sufﬁcient to assess the
efﬁcacy of enzyme supplement therapy. In patients with poor
response 72-hour fecal fat collection to measure steatorrhea is
suggested. Steatocrit seems to be highly correlated with fecal
fat content. However, it is measured on a random specimen
of stool, and the accuracy of the test depends on a high-
fat diet [77,89]. The 13C mixed triglyceride breath test has
been used to evaluate the efﬁcacy of pancreatic enzyme
supplementation in patients with chronic pancreatitis [77,88].
C.19: Is assessment of endocrine pancreatic function
recommended in chronic pancreatitis?
Statement (EL 4 − RGC): Assessment of endocrine
pancreatic function is recommended by measuring fasting
blood glucose levels.
Consensus Levels of Agreement:
A+ 59.2%; A 29.5%; A− 6.8%; D− 4.5%; D 0%; D+ 0%
As there is a high frequency of diabetes in the long-
term evolution of chronic pancreatitis, it is recommended
to measure fasting blood glucose levels. Although there
are several methods for assessing the insulin reserve in
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patients with pancreatic diabetes (basal or oral glucose
tolerance test, serum/urinary insulin or C-peptide determina-
tions, beta-cell maximal stimulation with glucagon, arginine
or tolbutamide), these methods do not have any impact
on decision making [99,100]. In a comparative study on
endocrine functional tests, serum C-peptide and glucagon
after arginine, but not serum insulin, were related to the
severity of pancreatitis [101].
C.20: Does pancreatogenic diabetes require pharmacological
and nutritional approaches differing from those of
type 1 and type 2 diabetes?
Statement (EL 4 − RGC): The treatment of pancreatic
diabetes does not differ from that of type 1 and type 2
diabetes.
Consensus Levels of Agreement:
A+ 77.3%; A 11.4%; A− 11.4%; D− 0%; D 0%; D+ 0%
Pancreatogenic diabetes differs from type 1 and type 2
because of higher risk for hypoglycemia and lower frequency
of ketoacidosis due to impaired secretion of glucagon [57].
Complications such as macro/microangiopathy, nephropathy,
neuropathy and retinopathy are as frequent as in type 1
diabetes [57]. Diet in pancreatogenic diabetes overlaps that of
type 1 diabetes, even though particular care should be taken
in the correction of malnutrition, vitamin and oligoelement de-
ﬁciencies, and prevention of hypoglycemia with fractionated
meals. With regard to insulin supply the reference glycemic
target is that of type 1 diabetes, except that it has to be slightly
elevated in cases of severe hypoglycemia. An educational
program should be undertaken in order to avoid the onset
of severe hypoglycemia; it should be focused on alcohol
abolition, oriented physical activity, fractionated meals, and
pancreatic enzyme adherence. There is no evidence for a role
of oral hypoglycemic drugs in the treatment of pancreatogenic
diabetes. The efﬁcacy of sulphonylurea, thiazolidinedione and
metformin has been reported [102]. In insulin-treated patients
caution should be exercised to avoid hypoglycemia.
C.21: Is pancreatic enzyme supplementation recommended
in patients with chronic pancreatitis and previous
pancreatic surgical intervention?
Statement (EL 5 − RGB): Pancreatic enzyme
supplementation is recommended in surgically treated
patients with pancreatic exocrine insufﬁciency.
Consensus Levels of Agreement:
A+ 82.6%; A 13%; A− 2.2%; D− 2.2%; D 0%; D+ 0%
Surgery can impair pancreatic function. Pancreatic ex-
ocrine insufﬁciency (PEI) develops in patients following
pancreatoduodenectomy and pylorus-preserving pancreato-
duodenectomy [86,103]. PEI is found in most patients after
partial pancreatic resection as well as in patients with
chronic pancreatitis [86,104]. Though most studies were not
speciﬁcally addressed to patients operated on for chronic
pancreatitis (EL 5), participants agreed upon a RG B
because in the presence of exocrine pancreatic failure enzyme
supplementation is indicated in any case.
C.22: Is pancreatic function testing useful for the diagnosis
of chronic pancreatitis?
Statement (EL 1c − RGB): Pancreatic function testing
may be used for the diagnosis of chronic pancreatitis when
imaging is not conclusive.
Consensus Levels of Agreement:
A+ 45.7%; A 17.4%; A− 15.2%; D− 6.5%; D 8.7%; D+ 6.5%
Chronic pancreatitis is an evolving process, and exocrine
function is progressively impaired from a reduced functional
capacity to exocrine failure in the late phase. New imaging
techniques usually allow a reliable and early diagnosis of
chronic pancreatitis. To detect mild or moderate exocrine
pancreatic impairment, invasive tests employing a hormonal
secretagogue maximally stimulating pancreatic secretion can
be useful. Such tests are sensitive but poorly speciﬁc, i.e.
they are not diagnostic [105,106]. Conversely, tubeless tests
of pancreatic function can detect severe exocrine insufﬁciency
only [107–109]. An endoscopic pancreatic test has recently
been proposed as an alternative tool [110,111]. In selected
cases, in the presence of clinical suspicion and minimal
morphological changes, direct function tests can help in
the diagnosis [112]. Tubeless functions tests (fecal elastase,
fecal chymotrypsin) can be used in the follow-up of selected
patients for identifying a progressive impairment in pancreatic
function by which the chronicity of the inﬂammatory process
can be conﬁrmed [107,109]. Fecal elastase-1 test does not
require a timed stool collection or special diet, has a high
negative predictive value for pancreatic insufﬁciency, and
a good sensitivity in patients with moderate and severe
pancreatic failure [18,113]. An 80% agreement was not
reached because of the lack of data comparing diagnostic
power of function tests and new imaging techniques.
3.2. Imaging (I)
Working party: Riccardo Manfredi (Coordinator), Lucia
Calculli, Claudio De Angelis, Rossella Graziani.
This section is devoted to the ability and accuracy of
diagnostic imaging in answering clinical questions related
to chronic pancreatitis. The role of diagnostic imaging
in depicting early changes of chronic pancreatitis is an-
alyzed. Magnetic resonance (MR) with MR cholangio-
pancreatography (MRCP) and dynamic MRCP following
secretin administration are discussed as tools that are able
to identify early changes, anatomical variants that may be
associated with an increased risk of chronic pancreatitis,
and to give functional information. The role of computed
tomography (CT) and of ultrasonography (US) in identifying
the presence and site of ductal stones and their use in
acute relapses and complications is considered. The role of
endoscopic ultrasound (EUS) in chronic pancreatitis and in
the differential diagnosis with pancreatic cancer is reported.
For overviews of CT and MRCP see Tables 2 and 3.
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Table 2
Minimal suggested CT technique and protocol
CT should be performed nowadays with multidetector technology (MDCT), with multiplanar reconstructions.
Multiplanar reconstruction (MPR) images, according to different planes, and curvilinear reconstruction images, according to main pancreatic duct, are useful in
chronic pancreatitis to assess ductal anatomy and abnormalities.
Minimum intensity protection (MinIP) and volume rendering (VR) reconstruction images may be useful in chronic pancreatitis in evaluating vascular anatomy
and abnormalities.
CT phase Technique/Parameters Findings
Un-enhanced CT + MPR and
3D reconstruction
Collimation: <2.5mm according to the technology available.




Contrast-enhanced pancreatic phase +
MPR reconstructions
Time delay: 35−45 s from the beginning of the injection
Bolus tracking: 18 s, from the aortic peak using a 90HU threshold
Contrast agent volume >130ml; with saline ﬂush
Injection rate: >3ml/s:
Collimation: <1mm






Contrast-enhanced portal venous phase +
MPR reconstructions
Time delay: 80−90 s from the beginning of the injection
Collimation: <2.5mm








Contrast-enhanced delayed phase + MPR Time delay: >180 s from the beginning of the injection
Collimation: <2.5mm
Anatomical coverage: from the diaphragm to the pelvis
Parenchymal ﬁbrosis
Washout/retention focal lesions
MPR Curvilinear reconstruction Ductal anatomy/abnormalities
MIP–VR–3D Vascular anatomy/abnormalities
I.1: Is transabdominal US a useful diagnostic imaging
technique to conﬁrm the clinical suspicion of chronic
pancreatitis?
Statement (EL 4 − RGC): Transabdominal US is useful in
conﬁrming the diagnosis of advanced chronic pancreatitis.
Consensus Levels of Agreement:
A+ 68.1%; A 25.5%; A− 4.3%; D− 2.1%; D 0%; D+ 0%
Transabdominal US is able to conﬁrm the diagnosis
of advanced chronic pancreatitis, since it identiﬁes the
thinning of the pancreatic parenchyma, the irregularity of the
pancreatic margins, dilatation of the main pancreatic duct and
of the side branches, and endoductal calciﬁed stones [114–
116]. Transabdominal US is not able to depict early chronic
pancreatitis, since it does not recognize parenchymal and
ductal changes indicative of the early phase of chronic
pancreatitis [114,117–127].
I.2: What is the most appropriate imaging technique for the
identiﬁcation of the site and the topography of pancreatic
stones?
Statement (EL 3 − RGC): The most appropriate imaging
technique to deﬁne the site and the topography of pancreatic
stones is CT.
Consensus Levels of Agreement:
A+ 59.6%; A 19.2%; A− 15.4%; D− 5.8%; D 0%; D+ 0%
CT without intravenous contrast media administration is the
diagnostic imaging modality of choice in diagnosing pancre-
atic stones typically present in advanced chronic pancreatitis.
Thanks to the high spatial and contrast resolution of this
tomographic technique, CT is able to detect ductal calcium
deposits [128–130]. Furthermore it localizes pancreatic stones
inside the lumen of the main pancreatic duct and/or side
branches, within the pancreatic head/body/tail, or diffuse. The
number and the size of the pancreatic stones are depicted
without intravenous contrast agent administration. Adminis-
tration of intravenous contrast agents helps in determining
whether they are in the main pancreatic duct and/or in the
side branches. The identiﬁcation of the site of ductal stones
is relevant for the endoscopic therapy. Transabdominal US
is also able to diagnose pancreatic stones, especially when
they present a diameter >5mm and they are localized in
the pancreatic head. However, transabdominal US is limited
by patient body habitus and meteorismus. Furthermore this
technique shows a lower spatial and contrast resolution, there-
fore a negative ultrasound does not exclude the presence of
stones [129,130]. Gadolinium-chelates enhanced MR imaging
combined with MRCP is a less suitable diagnostic imaging
modality for the diagnosis of pancreatic stones, since it does
not depict the stones directly but only indirectly as ﬁlling
defects within the pancreatic duct system. When the stones
are not completely surrounded by ﬂuid they can be missed,
especially when they are less than 3mm in size [131].
Conventional radiology is able to visualize pancreatic
stones, especially coarse stones. However it cannot distinguish
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Table 3
Minimal suggested MR/MRCP Technique and Protocol
Patients should fast for at least 5 hours before the examination, and approximately 200ml of superparamagnetic contrast medium or pure pineapple juice should
be given orally 30 minutes before the procedure to eliminate the interference of organs containing ﬂuid on the bilio-pancreatic tree.
MR Sequences Technique Findings
Axial chemical shift T1-weighted Gradient Echo












Axial and coronal T2-weighted Rapid
Acquisition with Relaxation Enhancement





Contrast-enhanced T1-weighted image during the
Pancreatic phase during 0.1mmol/kg body
weight of gadolinium-chelates injection at
2−2.5ml/s, 35−45 s following contrast media
administration
Dynamic study during gadolinium-chelates injection possibly
obtained by means of a 3D volumetric Gradient Echo pulse
sequence with fat saturation, along the axial plane
Same as CT
Contrast-enhanced T1-weighted image during the
portal venous phase, 75−80 s following contrast
media administration
Same as CT
Contrast-enhanced T1-weighted image during the
portal venous phase >180 s following contrast
media administration
Same as CT
MRCP 2D Half Fourier RARE heavily T2-weighted pulse sequence,
during breath-hold, along the most appropriate coronal/coronal
oblique plane demonstrating the pancreatic duct system as well




Dilated MPD and/or side branches
Dynamic MRCP during secretin administration Secretin (1 clinical unit/kg) is administered before the




Diffusion weighted images Signs of early chronic pancreatitis
their topography. EUS is comparable to CT in depicting
site and topography of pancreatic stones, being able to
visualize also very small stones (<3mm). EUS is a minimally
invasive imaging modality and is used as a problem solving
technique [127].
I.3: What is the imaging technique of choice to diagnose
early chronic pancreatitis?
Statement (EL 3a − RGB): MR imaging with MRCP,
before and after secretin administration, and EUS are
the most appropriate imaging techniques to diagnose
parenchymal and ductal changes in early chronic
pancreatitis.
Consensus Levels of Agreement:
A+ 71.2%; A 21.2%; A− 5.8%; D− 0%; D 1.8%; D+ 0%
Gadolinium-chelates enhanced MR imaging combined
with MRCP has nowadays substituted diagnostic endoscopic
retrograde cholangio-pancreatography (ERCP), because it is a
non-invasive technique and it is able to simultaneously assess
ductal and parenchymal changes typical of early chronic
pancreatitis [132].
MRCP shows a lower spatial resolution compared to ERCP,
however the administration of secretin during MRCP is able
to overcome this limitation.
Furthermore MRCP can be acquired dynamically during
intravenous secretin administration in order to non-invasively
obtain morphologic and functional information [133–139].
Recently, some authors have suggested the use of diffusion-
weighted (DW) imaging, dynamic gadolinium-chelates en-
hanced MR imaging and MRCP performed following in-
travenous injection of secretin: the measurement of ap-
parent diffusion coefﬁcient (ADC) from diffusion-weighted
images before and after secretin administration may aid
in the diagnosis of early chronic pancreatitis [138,140–
142].
EUS has recently shown its ability to diagnose early chronic
pancreatitis by assessing the morphological and structural
changes of the pancreatic parenchyma. The meaning of these
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pancreatic morphological changes in asymptomatic patients
with normal pancreatic laboratory tests is not clear [143–
147].
I.4: What is the imaging technique of choice to diagnose
advanced chronic pancreatitis?
Statement (EL 3a − RGB): Transabdominal US, CT and
MR are able to diagnose advanced chronic pancreatitis.
Consensus Levels of Agreement:
A+ 70%; A 20%; A− 10%; D− 0%; D 0%; D+ 0%
Advanced chronic pancreatitis has signs that can be
depicted by means of US, CT and/or MR imaging, therefore
the choice should be based on the local expertise, availability,
and costs. In advanced chronic pancreatitis, EUS can be used
for tissue characterization and treatment planning, because of
its invasiveness.
However considering medical need and availability, most
likely intravenous contrast-enhanced CT is the modality
that is able to assess most of the morphological signs
typical of advanced chronic pancreatitis and its complica-
tions [119,127,145,148–150].
Speciﬁc clinical needs can be answered by gadolinium-
chelates enhanced MR imaging, with MRCP during se-
cretin administration, to assess the pancreatic exocrine re-
serve [132,138,151–153].
Most papers, however, suggest integration between the
different imaging modalities, in order to better answer the
different clinical questions.
I.5: Is dynamic MRCP during secretin administration useful
in patients with chronic pancreatitis?
Statement (EL 3a − RGB): Dynamic MRCP during
secretin administration is a problem-solving technique to
identify initial morphological changes of the pancreatic duct
system, hydrodynamically signiﬁcant strictures and to assess
the pancreatic exocrine reserve.
Consensus Levels of Agreement:
A+ 57%; A 36%; A− 7%; D− 0%; D 0%; D+ 0%
Gadolinium-chelates enhanced MR imaging, combined
with dynamic MRCP during secretin administration, is useful
in patients with chronic pancreatitis [132,152,153].
In particular, in early chronic pancreatitis dynamic MRCP
during secretin administration is useful in conﬁrming the
clinical suspicion; and in identifying the causes of recurrent
chronic pancreatitis, by identifying initial morphological
changes of the pancreatic duct system and speciﬁcally of the
side branches [152].
In advanced chronic pancreatitis, dynamic MRCP during
secretin administration is useful in identifying hydrody-
namically signiﬁcant strictures and to assess the pancreatic
exocrine reserve.
However, the cost–beneﬁt relation is still under investiga-
tion [132,138,152,153].
I.6: What is the imaging technique of choice to identify
pancreatic malformations in patients with chronic
pancreatitis?
Statement (EL 4 − RGC): MRCP or EUS are the
most accurate imaging techniques to identify pancreatic
malformations in patients with chronic pancreatitis.
Consensus Levels of Agreement:
A+ 61%; A 26.8%; A− 7.4%; D− 0%; D 2.4%; D+ 2.4%
Good-quality studies investigating the presence of pancre-
atic duct malformations in chronic pancreatitis are lacking.
All these malformations can be observed mainly with MRCP,
with or without secretin administration, and few studies
have been carried out using EUS [119,154–160]. We suggest
that MRCP is the imaging technique of choice to identify
pancreatic malformations in patients with chronic pancreatitis,
also considering its lack of invasiveness. The use of secretin
administration and dynamic MRCP improves the diagnostic
accuracy of the technique [161,162].
Gadolinium-chelates enhanced MR imaging combined with
MRCP has nowadays substituted diagnostic ERCP, because
of its non-invasiveness and its ability to depict ductal
malformations.
I.7: What is the imaging technique of choice for the
assessment of a patient with chronic pancreatitis and
ﬂare of the disease?
Statement (EL 4 − RGC): CT is the technique of choice
in patients with chronic pancreatitis and ﬂare of the
disease.
Consensus Levels of Agreement:
A+ 72.2%; A 3.6%; A− 9.3%; D− 1.9%; D 5.6%; D+ 7.4%
Intravenous contrast-enhanced CT is able to conﬁrm the
diagnosis, assess severity of the ﬂare and identify complica-
tions of the disease, addressing the same issues as in acute
pancreatitis [127,131,163,164].
Gadolinium-chelates enhanced MR imaging combined with
MRCP is useful in assessing some complications of chronic
pancreatitis and ﬂare of the disease because of its high contrast
resolution.
MR imaging/MRCP is able to identify ruptures of the
main pancreatic duct, assessment of drainability of peri-
pancreatic collections, presence of methemoglobin, and
thoraco-abdominal ﬁstulae, because of its higher contrast
resolution. In particular, MRCP easily shows loss of integrity
of the main pancreatic duct, with or without pancreatic
ﬁstulas. T2-weighted MR images identify solid debris,
clots and methemoglobin within peripancreatic ﬂuid col-
lections. All of this information is useful for treatment
planning [162].
EUS can also be useful in assessing the feasibility of
endoscopic drainage of peripancreatic ﬂuid collections or
post-acute pseudocysts, in selected patients.
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I.8: What is the most reliable procedure in detecting
malignancy in patients with chronic pancreatitis, when
clinically suspected?
Statement (EL 4 − RGC): The diagnostic tool most
reliable in tissue characterization is represented by EUS
with ﬁne needle aspiration (FNA).
Consensus Levels of Agreement:
A+ 70.8%; A 22%; A− 4.8%; D− 2.4%; D 0%; D+ 0%
The differential diagnosis between inﬂammatory and ma-
lignant masses and early detection of malignancy in patients
with known chronic pancreatitis remains a difﬁcult task for all
diagnostic imaging techniques, even for EUS with or without
FNA [165,166].
3.3. Endoscopy (E)
Working Party: Armando Gabbrielli (Coordinator), Luigi
Ghezzo, Alberto Mariani, Massimiliano Mutignani.
With the advent of modern and non-invasive imaging
techniques, the role of endoscopy in chronic pancreatitis
has become therapeutic. Since ductal obstruction can play
a role in the pathogenesis of pain in chronic pancreatitis,
endoscopic duct decompression seems to be a rational
approach [5,167]. Endoscopy is also employed for the
treatment of complications of the disease. Endoscopic therapy
is based on different techniques and procedures, such as
pancreatic sphincterotomy, extraction of pancreatic stones,
pancreatic and biliary stenting, and the drainage of pseudo-
cysts with conventional endoscopy or with endoscopic ultra-
sound (EUS). Extracorporeal shock wave lithotripsy (ESWL)
for pancreatic stones may be combined with endoscopic
procedures.
The selection of patients for endoscopic treatment of pain
and prevention of painful relapses, of jaundice, of biliary
and/or pancreatic strictures or stones, and of pseudocysts
is discussed. The results of endoscopic therapy should
be compared with those of derivative surgery, but few
comparative studies are available so far [168].
E.1: Is endoscopic therapy indicated in asymptomatic
patients with chronic pancreatitis and dilation of the
main pancreatic duct?
Statement (EL 5 − RGD): There is no indication to
endoscopically treat asymptomatic patients with dilation
of the main pancreatic duct.
Consensus Levels of Agreement:
A+ 84.6%; A 7.7%; A− 2.6%; D− 2.6%; D 2.6%; D+ 0%
The rationale for endoscopic drainage in patients with
asymptomatic main pancreatic duct dilation is to restore
pancreatic juice outﬂow and to prevent evolution toward
pancreatic exocrine and endocrine insufﬁciency, delaying the
process of glandular atrophy. In surgical literature a limited
number of studies showed an improvement of pancreatic func-
tion after pancreojejunostomy [169]. However, there are no
endoscopic studies evaluating the role of endoscopic treatment
on the outcome of endocrine and exocrine pancreatic function
in these patients.
E.2: Is endoscopic therapy effective for treating pain
associated with main pancreatic duct dilation in chronic
pancreatitis?
Statement (EL 3b − RGB): Endoscopic therapy is
effective in patients with pain and main pancreatic duct
dilation.
Consensus Levels of Agreement:
A+ 77.5%; A 20%; A− 2.5%; D− 0%; D 0%; D+ 0%
Endoscopic treatment is effective in short-term follow-up
in patients suffering from obstructive-type pain [170,171].
According to some studies [36,65,67], endoscopic therapy was
not able to modify the various physical and mental domains
evaluated by both the SF-36 [36,65] and SF-12 [67] ques-
tionnaire, whereas endoscopic therapy combined with ESWL
was able to signiﬁcantly improve some QoL scores (pain,
weight loss, fever and jaundice) and the global QoL in about
70% of patients during a short time interval (median 7 mo,
range: 5−9). Endoscopic therapy can affect the long-term
clinical outcome by decreasing both the hospitalization rate
for pain and the intake of analgesics [172,173]. Because of
the frequent coexistence of different ductal lesions in the same
patient, the effectiveness of endoscopic therapy is usually
the result of combined procedures, such as sphincterotomy,
stricture(s) dilation, stone(s) extraction, stent(s) placement.
The aim of all these endoscopic procedures is to restore
drainage of the main pancreatic duct. In the presence of
intraductal obstructing stone(s), endoscopic therapy may
be combined with ESWL. In two randomized controlled
trials, long-term results of endoscopic treatment of pain
compared to derivative surgery are conﬂicting [36,174].
Endoscopic therapy can be successfully repeated in case of
pain relapses [175,176]. The spontaneous burn-out of pain
in the natural history of chronic pancreatitis may interfere
in the assessment of efﬁcacy of endoscopic therapy [177].
Endoscopic drainage can be proposed as a ﬁrst-line treatment
in patients unﬁt for surgery or refusing surgery and can also
be useful as a “bridge to surgery” therapy [167,174].
E.3: Is endoscopic therapy indicated in chronic pancreatitis
with painful relapses, but without evidence of
obstruction and dilation of the main pancreatic duct?
Statement (EL 5 − RGD): There is no indication to
endoscopically treat patients without obstruction and
dilation of the main pancreatic duct.
Consensus Levels of Agreement:
A+ 75%; A 18.2%; A− 6.8%; D− 0%; D 0%; D+ 0%
In patients with frequent painful relapses, pancreatic
sphincterotomy is attempted to facilitate pancreatic juice out-
ﬂow. However, there is no evidence for its efﬁcacy in treating
pain in patients without duct dilation and obstruction.
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E.4: Should ESWL be combined with endoscopic therapy
in patients with pain and stones in the main pancreatic
duct?
Statement (EL 2c − RGB): ESWL should be combined
with endoscopic therapy in the presence of large and
obstructive stones of the main pancreatic duct.
Statement (EL 1b − RGA): In patients with stones in the
head or in the body of the pancreas, and without strictures
of the main pancreatic duct, ESWL alone is equally
effective as ESWL combined with endoscopic treatment.
Consensus Levels of Agreement:
A+ 65.2%; A 23.9%; A− 8.7%; D− 0%; D 0%; D+ 2.2%
Endoscopic stone extraction and duct decompression is lim-
ited by the size of the stones and presence of stricture [178].
ESWL overcomes the problem of the stone size by fragment-
ing the stones, thus facilitating endoscopic clearance of the
duct. ESWL is required in 36−68% of patients and successful
rates of stone clearance of the main pancreatic duct ranged
from 37% to 100% [115,120,173,179–187]. Use of ultrasound
instead of x-rays to locate pancreatic stones is associated
with a lower fragmentation rate [188,189]. Data regarding
mechanical or intraductal lithotripsy technique are limited
and showed it to be technically challenging, cumbersome
and requiring highly specialized equipment [190,191]. In a
randomised controlled trial, in selected patients (one or few
calciﬁcations in the pancreatic head or body with upstream
dilation of main pancreatic duct) ESWL alone reduced the
number of pain episodes similarly to ESWL combined with
endoscopic treatment, with signiﬁcantly lower cost [192].
E.5: What is the indication for unscheduled pancreatic stent
removal?
Statement (EL 3b − RGB): A pancreatic stent should be
removed in case of painful relapse associated with occlusion
or displacement of the stent.
Consensus Levels of Agreement:
A+ 70.8%; A 18.8%; A− 4.2%; D− 2.1%; D 4.2%; D+ 0%
Insertion of a pancreatic stent is indicated in case of
dominant main pancreatic duct stricture (prepapillary stricture
with upstream dilation). Current strategy calls for unsched-
uled stent replacement when patients become symptomatic
(abdominal pain) and pancreatic duct dilation is shown
by abdominal ultrasound or MRCP [175,193–196]. Early
removal of a pancreatic stent can be considered if it has no
effect on pain.
E.6: How long should pancreatic stenting policy be
pursued?
Statement (EL 3b − RGB): Pancreatic stenting should be
pursued for at least 6−12 months in presence of persistent
pain relief.
Consensus Levels of Agreement:
A+ 45%; A 35%; A− 15%; D− 2.5%; D 2.5%; D+ 0%
Currently there are two strategies in pancreatic stenting:
either removing the pancreatic stent after a period of
6−12 months irrespective of the resolution of the stricture of
the main pancreatic duct or substitution of pancreatic stents
until stricture disappearance [175,176,193–200]. Long-term
pain relief was experienced by two-thirds of patients after
12 months stenting, though resolution of the stricture was
observed in a minority of patients [176,193]. Calibration of
a single distal main pancreatic duct stricture with multiple
stents insertion (range 2−4 large-bore stents for 6 months)
is a promising approach recently described [198]. After
stent removal, stricture resolution was observed in 95% of
17 patients. After a mean of 38 months follow-up, 84% of
patients remained pain-free [198].
E.7: In the presence of common bile duct stenosis and
dilation, is biliary endoscopic drainage indicated in
asymptomatic patients with normal liver function
tests?
Statement (EL 5 − RGD): Endoscopic therapy is not
indicated in presence of common bile duct stenosis and
dilation in asymptomatic patients with normal liver function
tests.
Consensus Levels of Agreement:
A+ 78.6%; A 26.7%; A− 0%; D− 0%; D 2.4%; D+ 2.4%
Asymptomatic common bile duct dilation in patients with
normal liver function tests may be detected by imaging tech-
niques (MRCP, CT) in patients with chronic pancreatitis [201–
204]. There are no predictive factors available to stratify
the risk of developing cholestasis and secondary biliary
cirrhosis, and to determine which patients could beneﬁt from
an endoscopic therapy. Conservative management is highly
recommended in these patients [202,204].
E.8: Is endoscopic therapy indicated in patients with chronic
pancreatitis and cholestasis, jaundice or cholangitis?
Statement (EL 4 − RGC): Endoscopic therapy is indicated
as a temporary effective treatment of cholestasis, jaundice
or cholangitis in patients with chronic pancreatitis.
Consensus Levels of Agreement:
A+ 81.4%; A 16.3%; A− 2.3%; D− 0%; D 0%; D+ 0%
Plastic stent placement is effective for short-term resolution
of symptomatic biliary strictures. Stent malfunctioning with
clogging and septic complications are common. Morpholog-
ical resolution of stenosis in long-term follow-up studies
is obtained in no more than 10% of patients [205–207].
More aggressive endoscopic therapy, by placement of multiple
plastic stents, can obtain stricture resolution in 44−90% of
cases with a 13–48 months follow-up period after stent
removal [208–210]. Although the role of self-expandable
metal stents is well established for malignant obstruction, their
use in benign strictures including chronic pancreatitis is less
clear and controversial [211–213]. Clogging or dysfunction of
these stents is reported in 10−62% of the cases after a mean
follow-up of 22–50 months. As a deﬁnite treatment, stenting
should be reserved for patients with serious co-morbid disease
or who refuse surgery.
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E.9: Is endoscopy indicated for the treatment of pancreatic
pseudocysts?
Statement (EL 4 − RGC): Endoscopic therapy is indicated
in symptomatic or complicated non-hemorrhagic pancreatic
pseudocysts.
Consensus Levels of Agreement:
A+ 71.4%; A 19%; A− 4.8%; D− 4.8%; D 0%; D+ 0%
Most pancreatic pseudocysts are asymptomatic and resolve
spontaneously. Treatment of asymptomatic and uncomplicated
pseudocysts is not indicated, regardless of the size [214].
Pseudoaneurysms are relatively frequent in association with
pancreatic pseudocysts. Hemorrhagic pseudocysts are an
absolute contraindication for endoscopic drainage.
Although there is a lack of evidence, endoscopic drainage
may be preferred to surgical treatment because it has a
better risk/beneﬁt proﬁle, being less invasive and providing
an equally effective drainage, and it is the treatment of choice
in high-risk patients [215,216]. Moreover, endoscopy does
not exclude or compromise subsequent surgery. Standard
endoscopic treatment without EUS depends on luminal
bulging [217–222]. EUS signiﬁcantly improves the safety of
endoscopic drainage by visualizing the cyst (it could drain
cysts without bulging) and vascular structures [223–225].
Knowledge of the etiology of the pseudocyst, morphology of
main pancreatic duct (presence of stricture) and its correlation
with pseudocysts (communication or not) is also crucial
in planning endoscopic therapy. According to the D’Egidio
classiﬁcation [226], in type 3 pseudocysts (associated with
pancreatic ductal obstruction and chronic pancreatitis) the
collection can be drained by treating the ductal obstruction
and relieving ductal hypertension only. This can be achieved
by therapeutic transpapillary endotherapy only. In pseudocysts
due to necrotizing pancreatitis in chronic pancreatitis (type 2),
the transmural drainage technique is the treatment of choice.
3.4. Surgery: indications and options (S)
Working Party: Massimo Falconi (Coordinator) Gianpaolo
Balzano, Donata Campra, Giuseppe Zamboni.
For experts to write about the surgical treatment of chronic
pancreatitis would seem relatively simple. However, to ﬁnd an
evidence-based approach to the matter is extremely difﬁcult
and many questions still remain on both indications and
choice of operation.
The indications for treatment are usually related to the
presence of pain, deﬁned by severity, and degree of disability.
However, there is as yet no universally accepted deﬁnition of
signiﬁcant symptomatic pain and disability, nor consensus on
the interpretation of its pathogenesis. This is a considerable
problem, since pain trend is of fundamental importance in
validating the results of any chosen treatment. Moreover,
regarding the genesis of pain, there are two main pathogenetic
hypotheses. The ﬁrst is based on the assumption that the
pain is caused by increased intraductal and or parenchymal
pressure caused by decreased drainage of pancreatic juice
into the duodenum. The second, more recent theory asserts
that symptoms are due to the release of neurotransmitters
into the inﬂammatory mass, usually located in the head of
the pancreas. One’s belief in either theory has important
therapeutic implications. Supporters of the ﬁrst hypothesis
believe that the palliation of pain can be obtained by
improving pancreatic drainage, endoscopically or surgically;
meanwhile, supporters of the second theory maintain that
palliation can only be obtained by resection of as much of the
diseased gland as possible. In fact, these concepts are probably
complementary, and combined surgical procedures have been
extensively investigated and compared. However, we are not
yet in the position to distinguish which patients will beneﬁt
from which procedure.
Other, less common indications for surgery are compli-
cations which unequivocally require a surgical approach,
sometimes even urgently (e.g., pseudocysts, involvement of
the biliary tree and duodenum or preoperative suspicion of
neoplasia, hemorrhage). Over the last few years surgical mor-
bidity and mortality rates have become generally acceptable
and long-term results, especially on pain relief, are excellent
regardless of the procedure performed. In addition, in the
last few years many things have changed in the nosologic
framework of the disease, certain etiological factors have been
discovered, and endoscopic skills have improved, adding new
options to the therapeutic armamentarium. All of these facts
have resulted, at least in part, in a re-evaluation of the role of
surgery in the treatment of chronic pancreatitis and ultimately
the choice of intervention.
The purpose of these guidelines on surgical treatment of
chronic pancreatitis, although ambitious, is: (1) to highlight
those data that are based on randomized clinical trials; (2) to
present a rational reading of the present literature on those
points which are still controversial, and (3) ﬁnally to arrive at
a systematic approach to the surgical management of chronic
pancreatitis based on the different clinical pictures that usually
characterize the disease.
S.1: What are the indications for surgery in patients
with chronic pancreatitis without extrapancreatic
complications?
Statement (EL 4 − RGC): Disabling and severe pain is the
main indication for surgery.
Statement (EL 4 − RGC): The other indication for
surgery is suspicion of pancreatic cancer.
Consensus Levels of Agreement:
A+ 76%; A 11.6%; A− 11.6%; D− 0%; D 0%; D+ 0%
Pain is the most frequent symptom in chronic pancreatitis,
though it is variable in frequency and severity [227]. Although
no prospective randomized study has yet compared conser-
vative and surgical treatment, there is evidence that surgery
is effective in pain. Surgery, tailored to the presumptive pain
cause, provides lasting pain relief.
Eight randomized studies aiming to compare different
treatments have been performed to date [36,174,228–233].
One of them did not include pain relief among the study
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endpoints [233]. The other seven studies accounted for overall
302 surgically treated patients and documented a substantial
pain relief in most patients undergoing both derivative and re-
sective operations. Moreover, two randomized studies showed
signiﬁcant beneﬁt of surgery over endoscopic treatment for
pain control in chronic pancreatitis with pancreatic duct
obstruction [36,174].
Suspicion of cancer: Three different settings should be
considered: 1. the association between chronic pancreatitis
and pancreatic cancer [57,60]; 2. the need to distinguish
between central intraductal papillary mucinous neoplasms
(IPMN) and chronic pancreatitis to avoid incorrect conser-
vative management; 3. the need to diagnose an autoimmune
pancreatitis to avoid unnecessary resections. The improvement
in preoperative diagnostic tools (EUS, CT, MRI, PET,
histology, laboratory tests) allows the correct diagnosis in
most cases of malignancy suspicion. However, if the suspicion
of cancer cannot be ruled out, the patient should undergo
a resective operation and not a derivative one, to obtain
adequate material for histological diagnosis. The delay in the
treatment of pancreatic cancer due to misdiagnosis is often
fatal [234,235].
S.2: What are the indications for surgery in patients with
extrapancreatic complications of chronic pancreatitis?
Statement (EL 4 − RGC): Bile duct and duodenal
symptomatic obstructions are indications for surgery.
Statement (EL 4 − RGC): Symptomatic pseudocysts can
be treated by surgery or endoscopy.
Statement (EL 4 − RGC): Variceal bleeding due to splenic
vein thrombosis should be treated by splenectomy.
Statement (EL 5 − RGD): Prophylactic splenectomy may
be considered when a patient with asymptomatic gastric
varices due to splenic vein thrombosis is undergoing surgery
for other complications of chronic pancreatitis.
Consensus Levels of Agreement:
A+ 61%; A 24.4%; A− 7.3%; D− 4.9%; D 0%; D+ 2.4%
Bile duct obstruction occurs in about 6% of patients
with symptomatic chronic pancreatitis and can be effectively
treated by hepatico-jejunostomy [236]. Endobiliary stents
should be used for high-risk patients.
Duodenal obstruction occurs rarely (about 1%) [236] and,
when isolated, should be treated by gastro-jejunostomy. When
associated with other complications of chronic pancreatitis,
such as pain and/or biliary obstruction, it should be treated
with resective operations, such as duodenum-preserving
procedures or pylorus-preserving pancreatico-duodenectomy
(PPPD).
Pseudocysts in chronic pancreatitis occur in about one
third of patients [19]. Spontaneous regression is less frequent
in chronic than in acute pancreatitis [237]; in the subset
of alcoholic chronic pancreatitis spontaneous regression has
been described in 25.7% of cases and persistence without
symptoms in 23% [238]. There is neither a prospective
randomized study comparing conservative and interventional
treatment of pseudocysts, nor a comparison among different
interventional strategies. The risk of serious complications of
asymptomatic chronic pseudocysts has been rarely assessed,
but it seems to be <10% [214,239]. Therefore asymptomatic
pseudocysts should be treated conservatively by ﬁrst instance,
irrespective of size or duration. Percutaneous drainage should
not be performed in chronic pseudocysts [240,241], whereas
both surgical and endoscopic treatments are effective to
manage symptomatic pseudocysts [242]. However, percu-
taneous and endoscopic treatments have sometimes been
associated with a high rate of complications, raising doubts
on the role of non-operative treatment as the ﬁrst-line
approach [243,244]. Surgically, pseudocysts can be treated
by anastomosis with a Roux-en-Y jejunal loop or with the
stomach, or by lateral pancreatico-jejunostomy alone in case
of dilated duct (>7mm) [245]. When endoscopic treatment is
preferred, endoscopic ultrasound-guided drainage seems safer
than conventional endoscopic drainage [223].
Splenectomy is clearly indicated in case of symptomatic
splenic vein thrombosis (variceal bleeding), whereas a pro-
phylactic role for splenectomy is controversial [246–248].
A good compromise should be to perform a concomitant
prophylactic splenectomy when a patient with left-sided portal
hypertension and evidence of asymptomatic gastric varices
(at endoscopy or CT) is operated for other complications of
chronic pancreatitis [248].
S.3: Should surgery be indicated in patients with
asymptomatic chronic pancreatitis and ductal
obstruction?
Statement (EL 2b − RGB): Surgical decompression of
the main pancreatic duct is not mandatory, but it may
be considered in patients with asymptomatic chronic
pancreatitis and ductal dilation (>7mm) to prevent the
progression of exocrine and endocrine insufﬁciency.
Consensus Levels of Agreement:
A+ 40%; A 31.1%; A− 22.2%; D− 4.4%; D 0%; D+ 2.2%
Although surgery is generally considered only in the late
stages of chronic pancreatitis, an alternative policy supporting
early operation in patients with mild disease and dilated main
pancreatic duct has been proposed since 1988. In particular,
the natural rate of impairment of pancreatic exocrine and
endocrine function was signiﬁcantly delayed by pancreatico-
jejunostomy as compared with a non-operated group [249].
This notion has been further addressed in a small subset of
randomized patients: after a mean follow-up of 39 months,
patients with mild chronic pancreatitis and associated main
pancreatic duct dilation who underwent an early derivative
procedure showed a diminished rate of progressive functional
impairment [169].
Moreover, in patients with chronic pancreatitis with main
pancreatic duct dilation (>7mm) and an associated pseudo-
cyst larger than 6 cm in diameter, surgical drainage alone
has proven to be more effective than percutaneous and/or
endoscopic techniques in a non-randomized study [250].
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Evidence in favor of a positive impact of operative
decompression on pancreatic dysfunction can also be ex-
trapolated by a recent experimental randomized study com-
paring early versus late surgical drainage for obstructive
pancreatitis, showing that an early operation leads to a better
recovery of histological changes and pancreatic exocrine
function [251].
According to these ﬁndings, the presence of main pan-
creatic duct dilation (>7mm) may represent “per se”
an indication for surgical decompression in asymptomatic
patients. However, a randomized controlled trial comparing
early surgical decompression of pancreatic duct as opposed to
primary or prolonged endoscopic drainage is warranted, and
major reservation accompanied the agreement for surgery in
one in ﬁve participants.
S.4: When is the appropriate timing for surgery in painful
chronic pancreatitis?
Statement (EL 5 − RGD): Pancreatic surgery should be
performed after failure of medical treatment and to avoid
narcotic addiction, and decided in a meeting of the patient
with an experienced surgeon and a gastroenterologist.
Consensus Levels of Agreement:
A+ 58.3%; A 27.1%; A− 4.4%; D− 4.4%; D 4.4%; D+ 2.2%
Studies evaluating the natural course of pain in chronic
pancreatitis have documented a variable percentage of patients
(47−80%) achieving spontaneous pain relief in advanced
chronic pancreatitis (10–15 years from onset) [19,252].
However, remission is unpredictable and a percentage of
patients will suffer of pain indeﬁnitely. The strategy of
waiting for spontaneous pain relief has been deﬁned not
reliable by the American Gastroenterological Association [2].
There is no pain level to deﬁne the timing of oper-
ation, but a delay in treatment may affect quality of
life, increase medical and social costs [253] and cause
narcotic addiction. Of note, a previous history of non-opioid
substance abuse (like alcohol) was the strongest predictor
of narcotic dependence in a study on chronic non-cancer
pain [254].
S.5: Is surgery the treatment of choice in patients with
chronic pancreatitis who develop jaundice?
Statement (EL 3a − RGB): Surgical biliary drainage is
the treatment of choice in case of stricture with persistent
jaundice in chronic pancreatitis.
Consensus Levels of Agreement:
A+ 55.1%; A 24.5%; A− 8.2%; D− 6.1%; D 4.1%; D+ 2%
Advanced chronic pancreatitis is frequently complicated by
common bile duct strictures and jaundice. In some instances
jaundice may be recurrent or persistent, with a slightly
increased risk of secondary biliary cirrhosis. Management
decisions are largely dictated by the duration of jaundice,
morphologic appearance of stricture, associated symptoms
(e.g. pain), as well as by the suspicion of an underlying
malignancy. A conservative approach has been advocated in
minimally symptomatic patients with transient jaundice and in
the absence of substantial alterations of liver function [255].
Recurrent jaundice or clinical presentation with cholangitis
are indications for endoscopic stent placement, which has
been shown to be a safe and effective procedure, with
a complication rate ranging from 4% to 7% [256,257].
The possibility of stent malfunctioning with clogging, dis-
lodgement and secondary infections must be taken into
account, so that a strict follow-up is warranted. Moreover,
the effectiveness of endoscopic palliation has been mostly
demonstrated in the short term, with long-term results being
more controversial [207,209]. Although jaundice improves
soon after stent insertion, complete regression of biliary
strictures occurs in a small proportion of patients, especially in
the presence of pancreatic calciﬁcations. In this regard, better
results seem to be achieved with multiple, simultaneous stents
rather than with a single stent [209].
Surgical biliary drainage has been recommended in case of
persistent jaundice (more than one month), severe clinical pre-
sentation (cholangitis, sepsis), secondary choledocolithiasis,
associated pancreatic head mass and/or inability to rule out
cancer [258].
There are no randomized controlled studies comparing
surgical versus endoscopic biliary drainage in chronic pan-
creatitis. Evidence has therefore been extrapolated by several
randomized studies and a recent meta-analysis evaluating the
same topic in pancreatic head carcinoma. From the meta-
analysis, there was no difference in relative risk for technical
success (RR 1.04, 95%CI 0.97–1.11) and therapeutic success
(RR 1.00, 95%CI 0.93–1.08) between stenting and surgery
in malignant obstructive jaundice. The relative risk of all
complications was signiﬁcantly reduced in those receiving
stents compared to surgery (RR 0.60, 95%CI 0.45–0.81)
with a p value of 0.0007. 30-day mortality showed a trend
in favor of stenting (RR 0.58, 95%CI 0.32–1.04), but this
was not statistically signiﬁcant (p = 0.07). The relative risk
of recurrent biliary obstruction prior to death/end of study
was 18.9 (95%CI 5.33–64.86) in favor of surgery, which
was statistically signiﬁcant (p< 0.00001) (i.e. less cholangitis,
clotting and gastric outlet obstruction). There were no
signiﬁcant differences in survival or quality of life between
the two treatment groups in any of the studies.
Accordingly, in the benign setting, surgery should be the
treatment of choice in case of a symptomatic biliary stricture
with jaundice persisting for more than one month. The optimal
procedure still remains unclear, different operations being
feasible, from a biliary by-pass (choledoco- or hepatico-
jejunostomy) to pancreaticoduodenectomy. In case of mass-
forming pancreatitis and/or suspicion of an underlying malig-
nancy, partial or complete pancreatic head resection should
always be carried out.
In non-operative candidates for local (e.g. portal caver-
noma) or general conditions (e.g. co-morbid diseases with
high operative risk), self-expanding metal mesh stents may be
considered.
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S.6: Are there any morphological criteria suggesting which
type of surgical intervention has to be preferred?
Statement (EL 5 − RGD): The type of surgical
intervention should be decided according to three main
morphological features: 1. main pancreatic duct dilation,
2. mass-forming chronic pancreatitis, 3. small pancreatic
duct disease.
Consensus Levels of Agreement:
A+ 72.9%; A 18.8%; A− 8.3%; D− 0%; D 0%; D+ 0%
No speciﬁc study can solve this question; data are taken
from reviews and clinical experiences. Chronic pancreatitis
has heterogeneous features that require different surgical
options, and a surgical approach tailored to morphological
criteria is suggested.
Traditionally three morphological patterns may be dis-
tinguished: (1) chronic pancreatitis with main pancreatic
duct dilation (7mm; large-duct disease); (2) chronic mass-
forming pancreatitis (including cystic dystrophy of the duode-
nal wall, i.e. groove pancreatitis); (3) chronic pancreatitis with
small/normal pancreatic duct (<7mm; small-duct disease).
Accordingly, the different operations traditionally proposed
are: drainage operation for large-duct disease, resection for
mass-forming chronic pancreatitis or for small-duct disease
(pancreatico-duodenectomy; PD) [2,259,260].
However, each traditional technique has a percentage of
long-term failure in pain relief [success rate: PD 66−89%,
lateral pancreatico-jejunostomy (LPJ) 6−84%, distal pancrea-
tectomy (DP) 57−81%] [261], possibly reﬂecting an incorrect
choice of operation based on morphological criteria.
Moreover, the morphological criteria, though being valid
principles, are less important in mixed operations [local
resection-lateral pancreatico-jejunostomy (LR-LPJ), duodeno-
preserving head resection (DPHR), Berne, V-shaped opera-
tion] that include resection and drainage at the same time and,
for this reason, are not so dependent on morphology.
S.7: When should pancreatic drainage surgery be chosen?
Statement (EL 5 − RGD): Drainage surgery should be
chosen in case of dilation of the main pancreatic duct
(7mm), after having ruled out malignancy.
Consensus Levels of Agreement:
A+ 62%; A 18%; A− 12%; D− 2%; D 4%; D+ 2%
Data were inferred from series dated back to 1980–
1990. Surgical drainage seems to be the ﬁrst treatment
required in patients with main pancreatic duct dilated to
preserve pancreatic function [262]. Delcore proposed drainage
operation in small-duct disease [263], but no beneﬁt was
proven [264]. The rationale of drainage operation is the
hypothesis that high pressure in the duct system and the
surrounding pancreatic parenchyma cause dilation of the
pancreatic duct and pain [265,266].
Drainage operation consists in a complete longitudinal
opening of the pancreatic duct and a side-to-side pancreatico-
jejunostomy without resection of the pancreatic tail as
proposed by Partington and Rochelle [267]. The surgical
drainage of the pancreatic duct has been improved between
1954 and 1960. In 1954 Zollinger [268] and Du Val [269]
ﬁrst proposed an internal retrograde drainage of the pancreatic
duct by means of a caudal pancreatico-jejunostomy with
resection of the pancreatic tail and an end-to-end pancreatico-
jejunostomy. In 1958 Puestow and Gillesby [270] improved
the retrograde drainage of the caudal pancreatico-jejunostomy
carrying out a longitudinal opening of the distal pancreatic
duct (after tail resection) and a side-to-side pancreatico-
jejunostomy. Finally, in 1960 Partington and Rochelle [267]
modiﬁed Puestow’s procedure to obtain a complete drainage
of the pancreatic duct by LPJ.
Mortality rates of drainage operation are very low (0−5%)
and short-term pain relief is obtained in about 80% of
patients [256].
S.8: What is the drainage surgery of choice in chronic
pancreatitis?
Statement (EL 4 − RGC): The lateral pancreatico-
jejunostomy (LPJ) procedure proposed by Partington and
Rochelle is the standard drainage surgery.
Consensus Levels of Agreement:
A+ 84.8%; A 10.9%; A− 2.2%; D− 2.2%; D 0%; D+ 0%
Lateral pancreatico-jejunostomy (LPJ) was proposed by
Partington and Rochelle. It consists in a complete opening
of the pancreatic duct up to one centimeter from the papilla
of Vater and a side-to-side pancreatico-jejunostomy by means
of a Roux-en-Y jejunal loop anastomized to the pancreatic
duct. LPJ has replaced Puestow’s operation. A wide drainage
of the entire pancreatic duct is recommended and the length of
the anastomosis is crucial for long-term outcome [271–274].
Therefore, the pancreatic duct must be opened completely and
a long lateral pancreatico-jejunostomy must be performed to
achieve complete drainage, avoiding a too short pancreatico-
jejunostomy.
LPJ provides a good pain relief (80%) and a good preser-
vation of endocrine and exocrine pancreatic function [275].
Moreover it is associated with low mortality and morbidity
rates [276–278]. In a prospective study, Maartense [103]
compared DPHR vs. LPJ and observed an improvement of
endocrine function after LPJ. However, LPJ has not been
evaluated in RCTs, even if it is widely used.
S.9: When is a mixed surgery (drainage + limited resection)
indicated?
Statement (EL 1b − RGA): A mixed surgery is indicated
in case of head mass-forming chronic pancreatitis, with or
without biliary tract involvement.
Consensus Levels of Agreement:
A+ 58.7%; A 23.9%; A− 10.9%; D− 2.2%; D 2.2%; D+ 2.2%
Different procedures that combine drainage and limited
resection have been proposed (DPHR, LR-LPJ, Berne pro-
cedure, V-shape operation) [279–282]. The mixed operations
should be the ideal interventions for chronic pancreatitis be-
cause they combine resection with drainage and theoretically
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may offer in a single operation: (a) better drainage of the
pancreatic ducts; (b) partial removal of the inﬂammatory
mass in the pancreatic head; (c) resolution of biliary tract
obstruction; (d) reduction of pancreatic parenchymal loss.
A recent meta-analysis [283], some RCTs [228,232,284]
and a recent review [266] have demonstrated the effectiveness
of such procedures. DPHR, LR-LPJ and Berne operation are
indicated when an inﬂammatory enlargement of the pancreatic
head has been found with or without dilation of the ductal
system. In LR-LPJ a coring-out excision of the pancreatic
head and uncinate process is performed, the pancreatic duct
is completely opened and a lateral pancreatico-jejunostomy is
performed. LR-LPJ may be chosen when the main pancreatic
duct is uniformly dilated or it appears like “chain of lakes”
and it could be performed also in the absence of a great
enlargement of the pancreatic head. DPHR consists of a
subtotal resection of the head of the pancreas conserving the
duodenum with a rim of pancreatic parenchyma and including
a complete division of pancreatic gland at the neck. Therefore
the restoration of the exocrine pancreatic secretory ﬂow from
the body and tail of the pancreas is performed by using the
ﬁrst jejunal loop as an interposition.
The Berne procedure is similar to DPHR, but avoids the
dangerous division of the pancreatic neck above the portal
vein, leaving a sheet of pancreatic parenchyma over the vein,
so it is safe in the case of portal hypertension [281]. Probably,
mixed operations have the best long-term results [266], but no
RCT has compared mixed and drainage operations, and the
better results of mixed operations are in comparison with old
drainage series. Moreover, mixed operations are demanding
techniques which require a higher surgical skill than LPJ.
S.10: What is considered the mixed procedure (drainage +
limited resection) of choice?
Statement (EL 1b − RGA): Local resection-lateral
pancreatico-jejunostomy (LR-LPJ), duodenum-preserving
head resection (DPHR) or Berne operation have similar
results. The choice among these surgical procedures is
based on the surgeon’s experience.
Statement (EL 3a − RGB): V-shaped operation is the
treatment of choice when small-duct disease is present
along the pancreatic duct without an inﬂammatory mass.
Consensus Levels of Agreement:
A+ 67.3%; A 24.5%; A− 6.1%; D− 2%; D 0%; D+ 0%
Some RCTs have analyzed the results of the mixed
procedures. Two RCTs [284,285] compared LR-LPJ vs.
DPHR and showed similar short-term and long-term results
for pain relief, pancreatic function, mortality rates and quality
of life. LR-LPJ is technically easier to perform than DPHR
because it does not require the section of the neck of the
pancreas [286].
One RCT compared Berne vs. DPHR [233]. The results
for quality of life did not differ signiﬁcantly, but the Berne
procedure is easier to perform and avoids the dangerous
division of the pancreatic neck above the portal vein.
Moreover it presents shorter operation time and hospital stay.
V-shaped operation, consisting in a triangular excision of
the entire anterior aspect of the pancreas with longitudinal
pancreatico-jejunostomy, is indicated when small-duct disease
is present along all the pancreatic duct without inﬂammatory
mass [233]. V-shaped operation is a safe and effective
treatment for small-duct disease with median pain score
decreased by 95% at follow-up [287].
S.11: When is pancreatico-duodenectomy (PD) indicated in
chronic pancreatitis?
Statement (EL 5 − RGD): Pancreatico-duodenectomy is
mandatory in patients with chronic pancreatitis when cancer
of the pancreatic head is not ruled out.
Statement (EL 1b − RGA): It can be indicated also in
case of pancreatic head mass, as an alternative to mixed
surgery.
Consensus Levels of Agreement:
A+ 60%; A 22.2%; A− 8.9%; D− 0%; D 4.4%; D+ 4.4%
Generally PD has good results in the treatment of chronic
pancreatitis [230,234,288–293]. However, with the advent of
the mixed techniques the role of the PD has been discussed.
Some RCTs and prospective studies have been published
comparing classical PD or PPPD vs. mixed techniques.
Mixed techniques have equal pain relief and better short-term
outcome than PD [229,230,293,294] while results in long-
term follow-up are similar [295,296].
Although mixed procedures represent the rational approach
to chronic pancreatitis, PD remains the most widely used
surgical intervention [297].
S.12: When is distal pancreatectomy (DP) indicated?
Statement (EL 4 − RGC): Distal pancreatectomy is
indicated when chronic pancreatitis mainly involves the
left side of the pancreas.
Statement (EL 4 − RGC): It is mandatory in case of tail
cancer suspicion.
Consensus Levels of Agreement:
A+ 77.6%; A 12.2%; A− 8.2%; D− 2.2%; D 0%; D+ 0%
Today DP is rarely performed in chronic pancreatitis and
few data are available from the last 10 years [298–300]. In
the past a high incidence of failure on pain relief after DP
was reported, with only 31% of good results [301]. This may
be due to poor patient selection. When DP was performed
with strict indication for predominantly left-side disease,
obstructive chronic pancreatitis or large pseudocyst [302,303]
pain relief was found in 88−90% of patients. Moreover, DP is
mandatory in the suspicion of tail cancer or for a pseudocyst
with concomitant bleeding. When splenectomy is indicated for
left-side portal hypertension, DP is the intervention of choice.
A pancreatico-jejunostomy should be performed to drain the
pancreatic stump after DP [299].
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S.13: When should total pancreatectomy be considered in
chronic pancreatitis?
Statement (EL 4 − RGC): Total pancreatectomy should be
considered after failure of previous surgery.
Consensus Levels of Agreement:
A+ 71%; A 24.4%; A− 6.1%; D− 0%; D 0%; D+ 2%
There is no prospective randomised study comparing
total pancreatectomy with other surgical treatments. In high-
volume pancreatic surgery centers, total (or near-total) pan-
createctomy can be performed with low mortality rate [304–
306], and seems to be effective in improving symptoms in
painful chronic pancreatitis [304,305,307–309]. The major
drawback of this operation is the “brittle” post-surgical
diabetes, with difﬁcult management owing to the absence of
counterregulatory hormones. To resolve this problem, islet
auto transplantation (IAT) has been proposed. Concomitant
IAT allows milder surgical diabetes, with a variable reported
percentage of short-term insulin independence, according to
the experience of different centers (from 0% to 55% [305]).
One third of 55 patients treated with total pancreatectomy and
IAT at the University of Minnesota were insulin-independent
after ten years [305].
S.14: When should intraoperative frozen section be done in
a patient with chronic pancreatitis?
Statement (EL 5 − RGD): Frozen sections’ examination
is indicated when pancreatic ductal carcinoma (PDC)
or intraductal papillary mucinous neoplasm (IPMN) are
intraoperatively suspected.
Consensus Levels of Agreement:
A+ 73.9%; A 15.2%; A− 2.2%; D− 6.5%; D 0%; D+ 2.2%
Differential diagnosis between chronic pancreatitis and
PDC based on frozen sections could be extremely difﬁ-
cult, with false negative and positive rates ranging from
10% to 30% [310]. To reach a correct diagnosis, the
knowledge of clinico-radiological data and the submission
of multiple biopsies is crucial, including lymph nodes
or any other suspicious lesion [311]. In PDC, the most
important pathological criteria are the loss of a lobular
pattern, the presence of angular contours with ruptured ducts,
intraluminar debris, the presence of solitary “naked” ducts
in the fat tissue, and the extrapancreatic inﬁltration with
perineural and vascular invasion [312,313]. Unfortunately,
chronic pancreatitis and PDC may sometimes look very
similar, especially in case of a well differentiated carcinoma.
The differential diagnosis between chronic pancreatitis and
IPMN is based on the presence or absence of dysplastic
modiﬁcation either in the main duct or in the branch
ducts [314]. Nevertheless, some limitations must be con-
sidered: (1) differential diagnosis between hyperplasia and
low-grade dysplasia can be difﬁcult (only moderate–high
grade dysplasia can be detected on frozen sections) [315];
(2) extensive inﬂammatory reaction with epithelial denudation
is frequently found in association with dilatation of the main
duct both in chronic pancreatitis and in IPMN. The submission
of additional biopsies in the search of the lining epithelium has
to be considered, when possible. However, in case of strong
clinical suspicion and negative intraoperative pathological
results, a standard resection is recommended.
4. Conclusion
These statements represent the ﬁrst comprehensive and
practical guidelines for the management of chronic pancre-
atitis. They resulted from a critical appraisal of the best
available evidence, and from expertise. A consensus process
contributed to their elaboration. This allowed to elaborate in
sequential steps the statements, to deﬁne a level of evidence,
to attribute a strength of recommendation, and to appreciate
the degree of agreement, making clinicians aware about their
quality and reliability.
Eighty-three per cent of statements received an agreement
rate of at least 80%. While still at over 67% agreement rate,
some topics (17%) did not reach such high agreement rate, for
instance, prevention of pain with antioxidants, role of smoking
withdrawal in pain control, function test and diagnosis of the
disease, size of risk of pancreatic cancer, but also surgery in
asymptomatic patients and duct obstruction, surgery in the
treatment of jaundice, and imaging in pancreatic stones.
The systematic analysis and appraisal of literature showed
that the level of evidence in this disease is high or good
(evidence level 1−2) for almost 40% of the statements, but it
remains moderate or low in some areas, such as imaging and
surgery, though excellent papers have been published on some
speciﬁc surgical topics. A or B strength of recommendation
was attributed to 45% of the statements. However, available
knowledge is represented by expert opinion in almost 20% of
the statements.
These guidelines represent a useful tool for approaching
chronic pancreatitis in a clinical setting. However, the
comprehensive process of their elaboration clearly suggested
that further clinical research, better in quality, is needed for
the management of chronic pancreatitis.
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